News Center
Home > News Center > Content Pages
Caris Molecular Intelligence Tumor Profiling Identifies Potential Responders to Anticancer Therapy A

Caris Molecular Intelligence Tumor Profiling Identifies Potential Responders to Anticancer Therapy Across a Range of Tumor Types

IRVING, Tex., Sept. 28, 2015 – Caris Life Sciences®

Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of three separate datasets in which Caris Molecular Intelligence®, the company’s panomic comprehensive tumor profiling service, facilitated the identification of potential responders to anticancer therapy across a range of tumor types. Results from the three studies, presented during a poster session at the 2015 European Cancer Congress (ECC2015) in Vienna, Austria, shed light on potential treatment strategies for patients whose tumors harbor BRCA1 and BRCA2 mutations, BRAF mutations, and aberrantly expressed ALK oncogenes, respectively.

“As more is learned about the biomarker expression patterns of various tumor types, it is becoming increasingly important to match that knowledge with clinical evidence of response to specific classes of anticancer agents,” said Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. “The data presented at ECC2015 further demonstrates how tumor profiling is helping practicing oncologists devise personalized treatment plans based on the molecular characteristics of individual patients’ tumors.”

BRCA1 and BRCA2 Mutations in Epithelial Ovarian Tumors (abstract #2771)
In one ECC2015 poster presentation, a team of researchers led by Thomas Herzog, M.D., of the University of Cincinnati College of Medicine used Caris Molecular Intelligence to analyze 1,691 epithelial ovarian cancer (EOC) tumor samples to identify BRCA1 and BRCA2 mutations in various histological subtypes of EOC, and to identify molecular differences in EOCs with or without BRCA1 or BRCA2 mutations. Using Caris’ multiplatform profiling techniques, such as gene sequencing (Next-Generation Sequencing [NGS], Sanger and Pyro Sequencing), protein expression analysis (Immunohistochemistry [IHC]), and gene copy number and translocation analysis (Chromogenic or Fluorescence in situhybridization [CISH or FISH]), investigators observed deleterious and mutually exclusive BRCA1 and BRCA2 mutations in 9% and 5% of EOC tumors, respectively.

To read the entire article, CLICK HERE

>> Returns a list of pages
My Comments

0  Comments Currently

Related Category
Promotion Products
  • Partners
  • Links
USCAP  |   CAP  |   IAP  |   TPIS  |   ASC  |   CAP-ACP  |   ASIP  |   AMP  |   ASCP  |   CAPA  |  
Home  |  News  |  Journals  |  Cases  |  Lectures  |  Experts  |  Telepath  |  Research  |  Conferences  |  Job_Position  |  Books  |  Sponsors
2009-2015 All Rights Reserved GoPath Diagnostics, LLC.